SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults.

Matthew E LevyEvanette BurrowsVanessa ChilundaPamala A PawloskiPhillip R HeatonJoseph GrzymskiJason D GoldmanLisa M McEwenDana WymanAndrew Dei RossiHang DaiMagnus IsakssonNicole L WashingtonTracy BaslerKevin TsanJason NguyenJimmy RamirezEfren SandovalWilliam LeeJames LuShishi Luo

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

Keyphrases

sars cov
respiratory syndrome coronavirus
primary care
adverse drug
early onset
antiretroviral therapy
combination therapy